Instil Bio Inc.

15.46
0.16 (1.05%)
At close: Apr 17, 2025, 3:59 PM
15.46
0.00%
After-hours: Apr 17, 2025, 04:09 PM EDT
1.05%
Bid 14.87
Market Cap 101.37M
Revenue (ttm) n/a
Net Income (ttm) -74.14M
EPS (ttm) -11.39
PE Ratio (ttm) -1.36
Forward PE -1.06
Analyst Buy
Ask 16.25
Volume 35,503
Avg. Volume (20D) 83,675
Open 15.28
Previous Close 15.30
Day's Range 15.18 - 15.73
52-Week Range 9.62 - 92.00
Beta 1.76

About TIL

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize f...

Industry Biotechnology
Sector Healthcare
IPO Date Mar 19, 2021
Employees 14
Stock Exchange NASDAQ
Ticker Symbol TIL
Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for TIL stock is "Buy." The 12-month stock price forecast is $110, which is an increase of 611.74% from the latest price.

Stock Forecasts
3 months ago
+14.84%
Instil Bio shares are trading higher after Jefferi... Unlock content with Pro Subscription
5 months ago
-5.51%
Instil Bio shares are trading higher after the company reported better-than-expected Q2 EPS results.